Christopher S. Kiper
Known title: DirectorCIK: 0001432744
Christopher S. Kiper's purchase track record
Christopher S. Kiper has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 10/3/2024 | LFCR | $6.00M | +41.4% | +44.6% | -5.3% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| LFCR | ▲ Buy | Grant | 25,907 | — | 6/4/2026 | View on chart |
| LFCR | ▲ Buy | Grant | 19,506 | — | 7/15/2025 | View on chart |
| LFCR | ▲ Buy | Open Market | 1,311,312 | $5.4M | 10/3/2024 | View on chart |
| LFCR | ▲ Buy | Open Market | 152,102 | $624K | 10/3/2024 | View on chart |
| LFCR | ▲ Buy | Grant | 30,000 | — | 7/8/2024 | View on chart |
| LFCR | ▲ Buy | Grant | 18,182 | — | 6/1/2023 | View on chart |
| LFCR | ▲ Buy | Grant | 3,981 | — | 2/1/2023 | View on chart |
| LFCR | ▲ Buy | Grant | 5,906 | — | 1/9/2023 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 28, 2026
Lifecore Biomedical to be acquired by Webster Equity Partners
Lifecore Biomedical has announced it will be acquired by Webster Equity Partners in a deal valued at up to $663.7 million. Shareholders may receive up to $9.67 per common equivalent, combining cash and contingent value rights based on performance milestones. This transaction is significant as it represents a full exit for the company, with the potential payout exceeding the current average analyst target of $6.75.
Lifecore Biomedical to be acquired by Webster Equity Partners. Lifecore Biomedical has announced it will be acquired by Webster Equity Partners in a deal valued at up to $663.7 million. Shareholders may receive up to $9.67 per common equivalent, combining cash and contingent value rights based on performance milestones. This transaction is significant as it represents a full exit for the company, with the potential payout exceeding the current average analyst target of $6.75.